FY2024 EPS Estimates for Quanterix Reduced by Analyst

Quanterix Co. (NASDAQ:QTRX - Free Report) - Analysts at Leerink Partnrs decreased their FY2024 earnings per share estimates for shares of Quanterix in a report issued on Tuesday, January 7th. Leerink Partnrs analyst P. Souda now expects that the company will post earnings of ($0.94) per share for the year, down from their prior forecast of ($0.88). The consensus estimate for Quanterix's current full-year earnings is ($0.88) per share. Leerink Partnrs also issued estimates for Quanterix's Q4 2024 earnings at ($0.24) EPS, Q1 2025 earnings at ($0.26) EPS, Q2 2025 earnings at ($0.24) EPS, Q3 2025 earnings at ($0.18) EPS and FY2025 earnings at ($0.88) EPS.

Separately, TD Cowen boosted their target price on shares of Quanterix from $13.50 to $16.00 and gave the stock a "hold" rating in a report on Wednesday, November 13th.

Quanterix Trading Down 0.5 %

Shares of QTRX stock traded down $0.06 on Thursday, reaching $11.73. The company's stock had a trading volume of 357,166 shares, compared to its average volume of 332,573. The company has a market capitalization of $451.89 million, a price-to-earnings ratio of -11.17 and a beta of 1.33. The stock's fifty day simple moving average is $12.02 and its 200-day simple moving average is $12.69. Quanterix has a 1 year low of $9.87 and a 1 year high of $29.70.

Institutional Trading of Quanterix

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Portolan Capital Management LLC boosted its holdings in shares of Quanterix by 31.4% in the third quarter. Portolan Capital Management LLC now owns 2,520,686 shares of the company's stock valued at $32,668,000 after purchasing an additional 602,656 shares during the period. Easterly Investment Partners LLC lifted its holdings in shares of Quanterix by 26.5% in the 3rd quarter. Easterly Investment Partners LLC now owns 876,133 shares of the company's stock worth $11,355,000 after buying an additional 183,387 shares during the period. Geode Capital Management LLC grew its position in shares of Quanterix by 2.2% during the 3rd quarter. Geode Capital Management LLC now owns 858,667 shares of the company's stock worth $11,131,000 after buying an additional 18,231 shares in the last quarter. State Street Corp increased its stake in shares of Quanterix by 2.2% during the third quarter. State Street Corp now owns 836,443 shares of the company's stock valued at $10,840,000 after buying an additional 18,050 shares during the period. Finally, Emerald Advisers LLC raised its holdings in shares of Quanterix by 5.6% in the third quarter. Emerald Advisers LLC now owns 719,217 shares of the company's stock valued at $9,321,000 after acquiring an additional 38,230 shares in the last quarter. Hedge funds and other institutional investors own 86.48% of the company's stock.

Quanterix Company Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.